Canadian urological association

The Canadian Urological Association CUA does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, canadian urological association, physician and other qualified health provider with any questions regarding your medical condition.

Full-length guidelines are reserved for broader topics that require more comprehensive exploration. BPRs provide a more focused, concise summary of the best evidence available on common urological topics to help guide management decisions. Both formats have undergone official CUA guideline approval process. Reproduction of any part of the published CUA guidelines, consensus statements, and best practice reports requires the express written consent of the Canadian Urological Association CUA. McMaster Institute of Urology at St. Treatment of bladder dysfunction in children, February Male urethral stricture, October

Canadian urological association

Federal government websites often end in. The site is secure. Prostate cancer remains the most commonly diagnosed non-cutaneous malignancy among Canadian men and is the third leading cause of cancer-related death. In , an estimated 21 men were diagnosed with prostate cancer and men died from the disease; 1 however, prostate cancer is a heterogeneous disease with a clinical course ranging from indolent to life-threatening. Identifying and treating men with clinically significant prostate cancer while avoiding the over-diagnosis and over-treatment of indolent disease remains a significant challenge. Several professional associations have developed guidelines on prostate cancer screening and early diagnosis, but there are conflicting recommendations on how best to approach these issues. With recent updates from several large, randomized, prospective trials, as well as the emergence of several new diagnostic tests, the Canadian Urological Association CUA has developed these evidence-based recommendations to guide clinicians on prostate cancer screening and early diagnosis for Canadian men. The aim of these recommendations is to provide guidance on the current best prostate cancer screening and early diagnosis practices and to provide information on new and emerging diagnostic modalities. In order to develop these recommendations, the following questions related to prostate cancer screening and diagnosis were defined, a priori, to guide the specific literature searches and evidence synthesis:. The aim of answering the first four questions is to provide guidance on prostate cancer screening in general.

Thus, the use of mpMRI should not be considered for men whose clinical signs show no ambiguity regarding the diagnosis of clinically significant prostate cancer.

Federal government websites often end in. The site is secure. As we exited the pandemic, healthcare within Canada was forced to take stock of the unmet clinical care needs and assign priorities to address those demands. In order to best assist our members and their patients as we faced the post-pandemic new world order, CUA leadership felt it important to obtain the most updated information on the current state of urology in Canada. To that end, a census was developed and circulated to the CUA membership.

Federal government websites often end in. The site is secure. Preview improvements coming to the PMC website in October Learn More or Try it out now. Prostate cancer remains the most commonly diagnosed non-cutaneous malignancy among Canadian men and is the third leading cause of cancer-related death. In , an estimated 21 men were diagnosed with prostate cancer and men died from the disease; 1 however, prostate cancer is a heterogeneous disease with a clinical course ranging from indolent to life-threatening. Identifying and treating men with clinically significant prostate cancer while avoiding the over-diagnosis and over-treatment of indolent disease remains a significant challenge.

Canadian urological association

Federal government websites often end in. The site is secure. Preview improvements coming to the PMC website in October Learn More or Try it out now. It is well-described that neurological disorders can lead to urological complications, including: urinary incontinence, urinary tract infections UTIs , urolithiasis, sepsis, ureteric obstruction, vesicoureteric reflux VUR , and renal failure.

Potensic

Characteristics of prostate cancer detected by digital rectal examination only. The CUA active membership survey has provided an invaluable snapshot on the state of urology in Canada. Second, in order to identify studies not captured by existing guidelines, a search of the literature was conducted using MEDLINE to identify articles related to the screening and diagnosis of prostate cancer that were published between January 1, and February 2, Canadian Task Force on Preventative Health 8. Serum prostate-specific antigen in a community-based population of healthy men. Early detection of prostate cancer: AUA guideline. The updates are summarized herein. Numerous studies have documented the measured changes and fluctuations in PSA levels over time. Corporate Contributor 6. Screening and prostate-cancer mortality in a randomized European study. PHI 0.

The Canadian Urological Association CUA does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals.

In order to reach this decision, the CUA recommends that healthcare providers engage in a thorough discussion on the potential risks and benefits of PSA screening with their patients and that shared decision-making be performed. Age-specific reference ranges for serum prostate-specific antigen in black men. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. Pathological and clinical findings to predict tumor extent of nonpalpable stage T1c prostate cancer. Bruno Laroche E The higher above the median, the greater the risk; jtesting above the age of 75 years should be done with caution and only in very healthy men with little or no comorbidity, as a large proportion may harbour cancer that would be unlikely to affect their life expectancy, and screening in this population would substantially increase rates of over-detection; however, a clinically significant number of men in this age group may present with high-risk cancers that pose a significant risk if left undetected until signs or symptoms develop. Our aims are to maintain benefits and mitigate potential harms associated with screening. The potential delay in diagnosis in the small proportion of men at this age with clinically significant prostate cancer seems unlikely to lead to a missed opportunity for curative treatment. These recommendations are not directed towards men with known germ-line mutations associated with prostate cancer development e. Sampling a population requires less expense than an in-depth census, and yet can still provide meaningful information on the entire population of interest. In the six nomograms with adequate validation across several study populations, the discrimination properties for prostate cancer detection were moderate AUC 0. American Urological Association 3. The ERSPC study is a collection of randomized trials conducted across eight European countries and includes men aged 55 — The aim of answering the first four questions is to provide guidance on prostate cancer screening in general.